Treatment Set TS331634 is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Dermatophagoides Farinae; Cynodon Dactylon Pollen; Alternaria Alternata; Sorghum Halepense Pollen; Iva Annua Var. Annua Pollen; Cochliobolus Sativus; Phoma Destructiva; Pleospora Herbarum.
Product ID | 49288-0720_b29faef0-2249-45b7-974b-212faa8c91d8 |
NDC | 49288-0720 |
Product Type | Human Prescription Drug |
Proprietary Name | Treatment Set TS331634 |
Generic Name | Treatment Set Ts331634 |
Dosage Form | Injection, Solution |
Route of Administration | INTRADERMAL; SUBCUTANEOUS |
Marketing Start Date | 1986-10-31 |
Marketing Category | BLA / BLA |
Application Number | BLA102223 |
Labeler Name | Antigen Laboratories, Inc. |
Substance Name | DERMATOPHAGOIDES FARINAE; CYNODON DACTYLON POLLEN; ALTERNARIA ALTERNATA; SORGHUM HALEPENSE POLLEN; IVA ANNUA VAR. ANNUA POLLEN; COCHLIOBOLUS SATIVUS; PHOMA DESTRUCTIVA; PLEOSPORA HERBARUM |
Active Ingredient Strength | 2000 [AU]/mL; [BAU]/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL |
Pharm Classes | Allergens [CS],Insect Proteins [CS],Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [CS],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS] |
NDC Exclude Flag | E |
Listing Certified Through | 2017-12-31 |
Marketing Start Date | 1986-10-31 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA102223 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 1986-10-31 |
Inactivation Date | 2019-10-21 |
Ingredient | Strength |
---|---|
DERMATOPHAGOIDES FARINAE | 2000 [AU]/mL |
SPL SET ID: | 4774e45e-d34c-4520-bf4c-6f46e98a0a8c |
Manufacturer | |
UNII |
|
Pharm Class PE | |
PHarm Class EPC | |
NUI Code |